Memory, Roche Rewrite Deal To Support Phase IIa Trial In Schizophrenia Cognitive Impairment Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche agrees to extra milestone payment for nicotinic alpha-7 agonist MEM 3454, but relinquishes rights to PDE4 inhibitor program.
You may also be interested in...
Roche Licenses Memory’s Lead CNS Compound
Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.
Roche Licenses Memory’s Lead CNS Compound
Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.
Memory, Roche Widen Deal To Try Nicotinic Alpha-7 Agonist In Schizophrenia
MEM 3454 already known to boost cognition in Alzheimer’s patients.